This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Dr. Falk Pharma Gmbh. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Syoji Kondo: Innovator in Gastrointestinal Therapeutics
Introduction: Syoji Kondo is a prominent inventor based in Tokyo, Japan, known for his significant contributions to the field of gastrointestinal therapeutics. With a focus on treating inflammatory bowel disease, Kondo has developed an innovative enema formulation that aids patients in managing their conditions effectively.
Latest Patents: Kondo holds a unique patent for an "Enema for rectal application" that contains budesonide as the active ingredient. This invention is designed specifically to treat inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease, as well as to prevent relapses. The patent describes the administration of 1.5 to 2.5 mg of budesonide per dose, with a recommended dosage of 2.0 mg taken twice daily for a duration of six weeks. The enema is available in both foamy and liquid forms, providing flexibility for patient use.
Career Highlights: Syoji Kondo is affiliated with Dr. Falk Pharma GmbH, where he has dedicated his career to advancing therapeutic options for gastrointestinal disorders. His innovations have not only improved patient care but have also contributed to the pharmaceutical company's reputation as a leader in this specialized field.
Collaborations: Kondo works alongside esteemed colleagues, including Yoji Yamada and Toshifumi Kajioka, fostering an environment of collaboration and innovation. Together, they contribute to furthering advancements in medical treatments that aim to improve the quality of life for patients suffering from gastrointestinal issues.
Conclusion: Syoji Kondo's innovative approach to the treatment of inflammatory bowel diseases highlights the importance of targeted therapies in modern medicine. His pioneering patent for an enema application signifies a critical advancement in the field, showcasing the potential for innovation to address complex health challenges. As he continues his work with Dr. Falk Pharma GmbH and his team, Kondo remains a vital figure in the realm of gastrointestinal therapeutics.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile